Delivery Order SPE2DB22D1200-SPE2DB24FN4EW

Award Date 8/13/24
Potential Completion Date 8/14/24
Potential Value $38K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,653.06 delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Spiriva Respimat 2.5 mcg inhalation medication, with a performance period through May 2, 2025. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides comprehensive global...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Spiriva Respimat 1.25 mcg inhalation medication. The delivery order, valued at $3,482.04, is a firm fixed-price contract with a completion date of November 20, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This delivery order was awarded to Amerisourcebergen Drug Corp, Corporate Office Division, by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,962.60 fixed-price contract is for the supply of Spiriva Respimat 2.5 MCG Inhalation Medication in 4 Gram quantities. It is not a set-aside contract. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $13,275.83, is for the supply of Spiriva Respimat 2.5 mcg inhalation medication. The contract has an ultimate completion date of April 21, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA Troop Support Medical, valued at $999,999,999.00, which...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Spiriva Respimat 1.25 mcg inhalation medication. The fixed-price delivery order, valued at $2,705.64, has a period of performance through March 2025. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Spiriva Respimat 1.25 mcg inhalers, with a ceiling value of $1,074.78 and a completion date of February 18, 2025. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This is a delivery order contract awarded to AmerisourceBergen Drug Corp by the Defense Logistics Agency (DLA) for the supply of Spiriva Respimat 2.5 mcg inhalation medication. The contract has a ceiling value of $2,388.66 and a completion date of May 25, 2023. It is a firm fixed-price contract classified as a delivery order, with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor. This contract is part of a larger Indefinite Delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of SPIRIVA RESPIMAT 2.5 MCG INH 4GM. The contract has a ceiling value of $16,404.67 and a completion date of September 25, 2023. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,428.27, is for the procurement of SPIRIVA RESPIMAT 2.5 MCG INH 4GM, a medical product used for respiratory conditions. The Delivery Order was issued under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of SPIRIVA RESPIMAT 2.5 MCG INH 4GM. The contract has a firm fixed price of $2,780.00 and a completion date of June 30, 2025. This award is not set aside and is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical. The IDC provides a comprehensive global...
  • SPE2DB22D1200
    Indefinite Delivery Contract
  • SPE2DB22D1200-SPE2DB24FN4EW
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, valued at $38,073.44, for the supply of Spiriva Respimat 2.5 mcg inhalation medication. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is for a firm-fixed-price delivery of the pharmaceutical product with an ultimate completion date of August 14, 2024.

Generated 11/12/24, 9:09 AM